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Abstract
We previously developed methods for establishing CD8 regulatory T cell (Treg) clones from normal human peripheral blood
and demonstrated that these clones were capable of killing T cell receptor (TCR)-activated autologous CD4 T cells. Based on
phenotypic and functional characterization of the CD8 Treg clones, we have identified a corresponding population of
endogenous CD8 Treg in normal human peripheral blood. These cells appear morphologically as large lymphocytes with
abundant cytoplasm and have the following unique phenotype: CD3
+CD8
+CD161
2CD56
+. The majority of CD8 Treg express
CD45RA and CD62L with low or negative expression of CD45RO, CD25, CD27, CD28 and CCR7. The expression of CD94 and
NKG2a on CD8 Treg was elevated compared to conventional CD8 T cells. Following in vitro activation, this T cell subset is
capable of killing TCR-activated CD4 T cells. These studies identify an endogenous CD8 Treg population in humans and it
will now be possible to characterize these cells in a variety of clinical conditions.
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Introduction
Immune responses are controlled by various populations of T
cells with regulatory function. These regulatory T cells (Treg)
suppress activated immune cells thereby maintaining immune
system homeostasis and self-tolerance [1,2,3,4,5,6,7]. Although the
phenotype and function of CD4 Treg have been characterized in
great detail, CD8 Treg have not been well characterized. In
murine models, CD8 Treg contribute to resistance to experimental
allergic encephalomyelitis (EAE), a model for human multiple
sclerosis [8,9]. Adoptive transfer of CD122
+CD8
+ T cells prevents
development of abnormal T cells in CD122-deficient mice [10].
More recent studies have shown that CD8 Treg suppress
pathogenic autoreactive CD4 T cells via a Qa-1-restricted
pathway [11]. Genetic disruption of the inhibitory interaction
between these CD8 T cells and their target Qa-1-expressing CD4
T cells results in increased susceptibility to EAE [11,12] and
development of a lethal systemic-lupus-erythematosus-like auto-
immune disease [13]. CD8 Treg have also been identified in
patients with multiple sclerosis [14], ovarian carcinoma [15] and
HIV-infection [16]. Several phenotypes of CD8 Treg have
previously been reported including; CD8
+CD103
+ [17],
CD8
+CD25
+CD28
+Foxp3
+ [18], CD8
+CD28
2Foxp3
+ [19],
CD8
+CD122
+ [10], and CD8
+CCR7
+CD45RO
+IL10
+ [15]. It
is not clear whether different CD8 Treg subsets represent
independent populations or whether they reflect different charac-
teristics of a single population. However, one consistent functional
feature of CD8 Treg is that these cells act primarily through
suppression of activated CD4 T cells [10,11,20,21]. Moreover,
almost all studies on CD8 Treg have been conducted in murine
models and few studies have focused on CD8 Treg in humans.
Our limited understanding of CD8 Treg populations and the
inherent uncertainty of extrapolating from mouse models to
humans led us to develop a novel protocol to establish stable CD8
T cell clones with auto-regulatory activity from normal human
peripheral blood [22]. CD8 Treg clones effectively suppressed
activated CD4 T cells and expressed a variety of TCR Vb chains,
indicating that the CD8 Treg population in humans is polyclonal.
Suppression by CD8 Treg clones was cell contact-dependent,
involved CD11a/CD18 (LFA-1) and CD8 surface antigens and
resulted in lysis of CD4
+ target T cells. Moreover, suppression by
CD8 Treg was independent of the antigen-specificity of CD4
+
target T cells and HLA compatibility between effector and target
cells [22]. CD8 Treg clones were CD8ab
+T-
CRab
+TCRcd
2TCRVa24
2TCRVb11
2 and did not expressed
significant levels of CD28, CD103, CD122, CCR7 and IL-10.
Unlike CD4 Treg, which are largely defined by the expression of
Foxp3 [1,23,24], levels of Foxp3 expression in CD8 Treg clones
were not correlated with their suppressive activity [22]. The lack of
CD28, CD103, CD122, CXCR4 and CCR7 expression and
dissociation of Foxp3 expression from suppressive activity indicate
that CD8 Treg clones are different from the CD103
+,
CD28
2Foxp3
+, CD25
+CD28
+Foxp3
+, CD122
+ and
CCR7
+CD45RO
+IL10
+ CD8 Treg subsets previously reported.
Interestingly, CD8 Treg clones frequently expressed CD56 and
rarely expressed CD161 [22], even though CD56 and CD161 are
often co-expressed on NK and NKT cells [25,26].
The establishment of stable human CD8 Treg clones has
provided us with a consistent experimental system to characterize
human CD8 Treg in vitro and to identify phenotypic character-
istics that can be used to define the corresponding endogenous
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e59545population in vivo. In the present study, we describe a population
of CD3
+CD8ab
+CD161
2CD56
+Va24
2 T cells in normal human
peripheral blood that function as CD8 Treg. Like CD8 Treg
clones, these CD8 Treg kill TCR-activated CD4 T cells
independent of the antigen-specificity of CD4 target T cells and
HLA compatibility between effector and target cells.
Results
Presence of CD3
+CD161
2CD56
+ CD8 T Cell Subset in
Normal PBMC
CD56 and CD161 are natural killer (NK) cell and natural killer
T (NKT) cell surface markers [1,22,23,24,25,26], which are often
co-expressed. In contrast, Va24 and Vb11 are characteristic cell
surface markers for NKT cells [27,28,29]. CD8 Treg clones
expressed CD56, but were Va24
2Vb11
2 and generally did not
express CD161. This characteristic phenotype distinguished the
CD8 Treg clones from NKT cells and the dissociated expression of
CD56 and CD161 in CD8 Treg clones prompted us to examine
whether CD8 T cells expressing CD56 but not CD161 might
represent a unique in vivo population corresponding to the CD8
Treg clones. To examine whether a CD161
2CD56
+ CD8 T cell
subset exists, we analyzed PBMC from 22 anonymous healthy
donors that had been stained with fluorochrome-conjugated anti-
CD3, CD8a, CD56 and CD161 monoclonal antibodies. The
dominant subset of CD8 T cells was CD56
2 and CD161
2,
representing conventional CD8 T cells (CD8 Tcon).
CD3
+CD8
+CD161
+CD56
+ and CD3
+CD8
+CD161
+CD56
2 cells,
representing NKT cells were also present in all individuals.
However, there was a distinct population of CD8 T cells that
expressed CD56 but not CD161 in each individual (Figure 1A).
The percentage of this population varied widely from 0.2% to
31.3% of all CD8
+ T cells with a median of 3.2% and mean of
6.8%. Seventeen of the 22 donors had less than 10% CD8 T cells
that were CD161
2CD56
+ (Figure 1B). Since these were anony-
mous donor samples, we were not able to examine whether the
variable frequency of CD161
2CD56
+ CD8 T cells correlated with
gender and/or age. However, these results demonstrated that
CD3
+CD8
+CD161
2CD56
+ cells are a distinct phenotypic CD8 T
cell subset presented in human peripheral blood in healthy
individuals.
Cell Surface Antigens Expressed by CD161
2CD56
+ CD8 T
Cells
Further characterization of cell surface antigens expressed by
CD3
+CD8
+CD161
2CD56
+ cells demonstrated distinct patterns of
expression when compared with conventional
CD3
+CD8
+CD161
2CD56
2 T cells (CD8 Tcon) (Figure 2 and
3) and CD3
+CD8
+CD161
+CD56
+ NKT cells (Figure 3). The large
majority of CD3
+CD8
+CD161
2CD56
+ cells express the naı ¨ve cell
surface marker CD45RA and are negative for memory/effector
cell surface marker CD45RO. In contrast,
CD3
+CD8
+CD161
+CD56
+ NKT cells were consistently
CD45RA
2 and CD45RO
+. Both CD8 Tcon and CD8 Treg
subsets expressed CD62L (Figure 2 and 3), but the level of CD62L
expression level was significantly lower in CD8 Treg compared to
CD8 Tcon (Figure 3). CD27, a member of the tumor necrosis
factor receptor (TNFR) superfamily, is expressed on the majority
of CD4 and CD8 T cells, especially naı ¨ve T cells [30]. In our
analysis, CD27 was highly expressed on CD8 Tcon, however,
most CD8 Treg cells were CD27 negative or low. While the
coordinate expression of CD45RA
+CD45RO
2CD62L
+ suggested
that CD8 Treg have a naı ¨ve phenotype, these cells were
CCR7
2CD27
low/2CD28
2, suggesting that they were likely
antigen-experienced. CD8Tregwere also CD25 and CD69negative,
and expressed significantly higher levels of CD94 and NKG2a and
lower levels of CD127 compared with CD8 Tcon. Unlike the
ambiguous cell surface antigen expression pattern of CD8 Treg,
CD3
+CD8
+CD161
+CD56
+ NKT cells displayed the typical pheno-
type of effector cells. NKT cells were CD45RA
2C-
D45RO
+CD62L
2CCR7
2CD27
lowCD127
+CD28
hiCD69
+.T h u s ,
CD8 Treg express a unique pattern of cell surface antigens
(CD45RA
+CD45RO
2CD62L
+CCR7
2CD27
low/2CD25
2CD28
2),
which is distinct from both conventional CD8 T cells and NKT cells.
CD161
2CD56
+ CD8 T Cells Display Abundant Cytoplasm
To further characterize this population, CD161
2CD56
+ CD8
Treg cells (CD56
pos) from normal human PBMC were
purified by fluorescence-activated cell sorting (FACS).
CD3
+CD8
+CD161
2CD56
2 (CD56
neg) cells were collected simul-
taneously as conventional CD8 T cell controls. CD56
neg cells
displayed typical morphology of mature lymphocytes with a round
nucleus and little cytoplasm. In contrast,
CD3
+CD8
+CD161
2CD56
+ (CD56
pos) cells had abundant cyto-
plasm with occasional granules and irregular nuclei (Figure 4A).
These morphologic features are typical of activated T cells and
NK cells. Both CD56
pos (CD8 Treg) and CD56
neg cells (CD8
Tcon) were CD8b
+TCRVa24
2 (Figure 4B). Being
CD8b
+TCRVa24
2CD161
2 indicates that the CD56
pos T cell
population, like the CD56
neg T cell population, did not include
NKT cells [30].
CD8
+CD161
-CD56
+ T Cells Maintain Low Level Expression
of CD27 after Activation
To activate and expand CD8 Treg, we stimulated FACS-
purified CD8
+CD161
2CD56
+ cells with phytohemagglutinin
(PHA) in the presence of feeder cells. CD8 Treg (CD56
pos) cells
proliferated as robustly as CD8 Tcon (CD56
neg) cells cultured in
parallel. After activation, CD56
pos cells remained CD161
2Va24
2,
and maintained higher expression of CD94 and lower expression
of CD62L compared with expanded CD56
neg cells (Figure 5A and
5B). After in vitro expansion, both CD56
pos cells and CD56
neg
populations lost expression of CD45RA and became strongly
CD45RO positive. It has been reported that activation of T cells
via TCR/CD3 induces high surface expression of CD27 [30].
However, the expression of CD27 in CD8 Treg (CD56
pos) cells
remained low (Figure 5A and 5B).
Lysis of Activated Allogeneic and Autologous CD4
+ T
Cells by CD8
+CD161
2CD56
+ T cells
We have previously shown that human CD8 Treg-mediated
suppression requires TCR activation of CD4
+ target T cells but is
independent of the antigen-specificity of CD4
+ target T cells and
HLA compatibility between effector and target cells [22]. To
determine whether polyclonal CD8 Treg (CD56
pos) cells had
similar functional activity, CD8
+CD161
2CD56
+ and
CD8
+CD161
2CD56
2 T cells were FACS-purified, expanded
in vitro for 7–10 days and tested for cytolytic activity against an
allogeneic Epstein-Barr virus (EBV)-specific CD4 T cell clone
(S2B5) we previously established and used as target cells for CD8
Treg clones [22]. Activated CD8 Treg (CD56
pos) lysed the CD4
+
target cell clone (S2B5), but only after target cells were sensitized
through TCR activation with anti-CD3 monoclonal antibody. In
contrast, activated CD8 Tcon (CD56
neg ) cells had no specific lytic
activity in this assay, either with or without TCR activation of the
CD4
+ target cells (Figure 6A). To further examine their functional
activity, CD8 Treg (CD56
pos), CD8 Tcon (CD56
neg), and
CD161
2CD56
+ CD8 T Cells with Regulatory Function
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e59545Figure 1. CD161
2CD56
+ CD8 T cell subset in normal PBMC. (A) Existence of CD161
2CD56
+ CD8 T cell subset in normal PBMC. Flow cytometric
analysis of cell surface expression of CD3, CD8, CD161 and CD56 on PBMC from healthy donors. The left plot was gated on lymphocytes and the right
plot on CD8 T cells. Plots are representative of PBMC from 22 healthy donors. (B) Percentage of CD161
2CD56
+ CD8 T cells in total CD8 T cells. Each
dot represents one individual (n=22). Horizontal bars indicate the mean. Cell subset gating was as shown in part (A) right plot.
doi:10.1371/journal.pone.0059545.g001
Figure 2. Distinct cell surface antigen expression profile of CD161
2CD56
+ CD8 T cells. PBMC isolated from healthy donors (n=5) were
stained and analyzed as described in Materials and Methods. Plots shown are from one representative individual. Conventional CD8 T cells
(CD161
2CD56
2) are compared to CD8 Treg (CD161
2CD56
+) and Control (non-stained lymphocytes).
doi:10.1371/journal.pone.0059545.g002
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cytometric cell sorting. Sorted CD4 T cells, CD8 Treg and CD8
Tcon were expanded in the presence of PHA and feeder cells.
Activated CD8 Treg (CD56
pos) cells effectively killed anti-CD3
antibody-sensitized autologous polyclonal CD4 T cells, but not
non-sensitized cells. In contrast, activated CD8 Tcon (CD56
neg)
cells did not display significant cytotoxicity towards the autologous
polyclonal CD4 T cells with or without TCR activation of the
CD4
+ target cells (Figure 6B). In addition, we also isolated
allogeneic polyclonal CD4 T cells from PBMC and expanded
them in vitro with PHA stimulation for use as target cells.
Activated CD8 Treg (CD56
pos) cells but not CD8 Tcon (CD56
neg)
lysed allogeneic polyclonal CD4 T cells after target cells were
sensitized through TCR activation with anti-CD3 (Figure 6C).
Thus, like the CD8 Treg clones, activated CD8
+CD161
2CD56
+
T cells effectively killed TCR-activated CD4 T cells regardless of
the antigen-specificity of CD4
+ target T cells and HLA compat-
ibility between effector and target cells. Taken together, these
results suggest that the CD8
+CD161
2CD56
+ T cell subset in
normal PBMC corresponds to an endogenous population of CD8
Treg.
Discussion
In previous studies we established a panel of human CD8 Treg
clones that selectively suppress activated CD4 T cells in vitro [22].
Here we sought to identify and characterize a population of CD8
T cells in normal human peripheral blood that had similar
functional activity. Based on phenotypic and functional charac-
terization of the CD8 Treg clones, we identified a population of
Figure 3. Cell surface antigens expressed by CD161
2CD56
+ CD8 T cells. PBMC isolated from healthy donors were stained and analyzed as
described in Materials and Methods. Intensity of cell surface expression of various markers shown in each graph is compared for different CD3
+CD8
+
subsets: CD8 Treg (CD161
2CD56
+); conventional CD8 T cells (CD161
2CD56
2); and CD8 NKT cells (CD161
+CD56
+). Mean and standard deviation are
shown (n=5).
doi:10.1371/journal.pone.0059545.g003
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+CD161
2CD56
+ T cells in human peripheral blood that
that suppresses activated CD4 T cells and therefore functions as a
regulatory T cell subset.
The selection of CD3, CD8, CD56 and CD161 as potential
positive and negative markers of peripheral CD8 Treg was based
on the detailed phenotypic characterization of CD8 Treg and non-
Treg clones we had previously established. Since both sets of
clones were established in a similar method and differed primarily
by their ability to suppress autologous activated CD4 T cells, we
reasoned that the phenotypic comparison of these clones would
identify surface markers that could distinguish CD8 Treg from
conventional CD8 T cells in normal peripheral blood. When this
marker set was subsequently tested in 22 healthy individuals, each
donor was found to have a distinct population of
CD8
+CD161
2CD56
+ T cells. Morphologically, these cells have
moderate amounts of cytoplasm with occasional granules. Overall,
cells with this phenotype represented a median of 3.2% of CD8 T
cells. Although it is likely that this population remains heteroge-
neous and contains cells with other functional characteristics, it
appears that this relatively small CD8 T cell subset is present in all
normal individuals.
To determine whether CD3
+CD8
+CD161
2CD56
+ cells display
similar suppressive activity as CD8 Treg clones, cells with these
markers were purified from normal PBMC by flow cytometric cell
sorting, stimulated non-specifically with PHA and expanded
in vitro. Previous experiments had shown that CD8 Treg clones
Figure 4. CD161
2CD56
+ CD8 Treg are CD8ab
+Va24
2 cells with abundant cytoplasm. (A) Morphology of CD161
2CD56
+ CD8 Treg. PBMC
were stained as described in Materials and Methods. CD56
pos (CD3
+CD8
+CD161
2CD56
+) CD8 Treg and CD56
neg (CD3
+CD8
+CD161
2CD56
2) CD8 Tcon
were purified by cell sorting. Isolated CD56
pos and CD56
neg cells were stained with Wright-Giemsa stain and visualized using a bright-field
microscope. Photos are from one representative experiment of six. (B) Cell surface expression analysis of CD8b and Va24 on CD56
pos and CD56
neg
cells. CD56
pos (CD8 Treg) and CD56
neg (CD8 Tcon) were purified by fluorescence-activated cell sorting. Both subsets were CD161 negative. Sorted
cells were analyzed for expressions of CD8b and Va24 as described in Materials and Methods. Data are from one of four representative healthy
donors.
doi:10.1371/journal.pone.0059545.g004
CD161
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expansion in vitro in similar conditions, and this allowed us to
obtain relatively large numbers of cells needed for functional
experiments [22]. Following expansion in vitro,
CD3
+CD8
+CD161
2CD56
+ cells continued to express CD3,
CD8 and CD56 and did not acquire CD161 expression. There
were some changes in cell surface markers as these cells converted
from a naı ¨ve phenotype (CD45RA
+CD45RO
2) to an effector/
memory phenotype (CD45RA
2CD45RO
+). Most importantly,
these expanded cells exhibited functional activity that was identical
to the CD8 Treg clones previously established. When tested
against an allogeneic EBV-peptide specific CD4 T cell clone
(S2B5) and polyclonal autologous and allogeneic CD4 T cells,
expanded CD8 Treg were able to lyse target CD4 T cells but this
was only evident after activation of CD4 target cells with anti-CD3
monoclonal antibody. Conventional CD8 T cells expanded under
identical conditions were not able to kill CD4 target cells, with or
without anti-CD3 activation. These experiments do not address
the question of whether CD3
+CD8
+CD161
2CD56
+ cells display
CD8 Treg suppressive activity in the absence of activation in vitro.
In preliminary experiments, freshly isolated
CD3
+CD8
+CD161
2CD56
+ cells did not exhibit suppressive
activity in vitro without subsequent activation and expansion
in vitro. CD4 Treg do not require further activation in vitro to
exhibit suppressive functions but CD8 Treg may require activation
before suppressive activity is acquired. Further experiments to
address this important functional comparison with CD4 Treg are
Figure 5. Cell surface phenotype of PHA-activated CD8 Treg. (A) Representative histograms for cell surface antigen expression on PHA
activated CD8 Treg (CD56
pos) and CD8 Tcon (CD56
neg). CD56
pos and CD56
neg cells isolated from PBMC were stimulated with PHA and cultured in the
presence of feeder cells for 8 days before being analyzed for cell surface marker expression as described in Materials and Methods. Data shown are
from one of 5 representative healthy donors. (B) Activated CD56
pos cells maintained high expression of CD56 and CD94 and lower expression of
CD62L and CD27. CD8 Treg (CD56
pos) and CD8 Tcon (CD56
neg) cells isolated from PBMC were stimulated with PHA and cultured in the presence of
feeder cells for 9 to 16 days before being analyzed for intensity of expression of CD56, CD62L, CD27 and CD94 cell surface antigens. p-value was
calculated with unpaired two-tailed Student’s t-test. Mean and standard deviation are shown (n=5).
doi:10.1371/journal.pone.0059545.g005
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in vivo.
We used cell surface expression of CD56 without concomitant
expression of CD161 as the primary identifying feature of this
novel CD8 T cell subset. CD56 is a cell surface marker
characteristic of all human NK cells and 90% of NK cells also
express CD161 [31]. Conventional NK cells do not express CD3
and TCR but some of these cells express CD8aa homodimers
[32]. In mice, NKT cells were described as a subset of T cells in
thymus that expressed NK-associated cell surface antigen NK1.1
(CD161 in human) [33]. In humans, NKT cells are a heteroge-
neous group of cells that possess properties of both T cells and NK
cells [34,35]. NKT cells characteristically express CD3 and
CD161; most NKT cells express CD4 and few express CD8.
Only some NKT cells express CD56 and expression of CD56 is
therefore not a distinguishing marker for these cells. In contrast to
conventional T cells, NKT cells specifically recognize lipid
antigens presented by CD1d molecules. NKT cells typically
produce IFN-c, IL-4 and other cytokines upon activation and are
not directly cytolytic. Classical NKT cells (also termed invariant
NKT), which constitute more than 80% of NKT cells, express a
canonical Va14-Ja18 a chain with a variable Vb8, 27, or 22 b
chain in mouse or Va24-Ja18/Vb11 in human. Non-classical
NKT cells in the mouse express a variety of rare but recurrent,
CD1d-reactive Va3.2-Ja9/Vb8, Va8/Vb8, and other TCRs
[28,29]. In contrast to both conventional NK and NKT cells,
the CD8 Treg we identified in human peripheral blood express
CD3, CD8ab, TCRab and CD56 but not CD161, Va24 or Vb11
(data not shown). CD8 Treg are highly lytic towards activated
CD4 T cells regardless of HLA compatibility. Finally, CD8 Treg
do not secrete high levels of IL-4 upon CD3 activation though the
production of IFN-c is greatly enhanced [22]. Taken together,
these results indicate that the CD3
+CD8ab
+T-
CRab
+CD161
2CD56
+Va24
2 Treg subset we identified in
normal peripheral blood is phenotypically and functionally distinct
from both NK and NKT cells.
Further studies demonstrated that CD8 Treg in peripheral
blood displayed an unusual pattern of cell surface antigens.
Typically, these cells were CD45RA
+ CD45RO
2 CD62L
+
CCR7
2 CD27
low/2 CD25
2 CD28
2 CD69
2CD127
low. Conven-
tional naı ¨ve CD8 T cells are usually CD45RA
+ CD45RO
2
CD62L
+ CCR7
+ CD27
+ CD25
2 CD28
+ CD69
2 CD127
+, while
conventional effector/memory CD8 T cells are generally
CD45RA
2 CD45RO
+ CD62L
2 CCR7
2. Although CD62L and
CCR7 are retained on central memory T cells, these cells are
CD45RA
2CD45RO
+ [36]. Clearly, this new T cell subset cannot
be readily categorized either as conventional naı ¨ve T cells or
effector/memory T cells. However, unusual expression of these
cell surface antigens has been previously reported. For example, it
was reported that a new subset of CD8 T cells that are CD45RA
hi
CD27
hi CD127
low CD28
low HLA-DR
hi might represent naive T
cells that have recently received homeostatic signals [37], while
expression of CD45RA on CCR7
2 CD8 T cells during viral
infections may be a marker for terminally differentiated cells [38].
Further studies are needed to determine whether CD3
+ CD8
+
CD161
2 CD56
+ cells are naı ¨ve or antigen-experienced.
Figure 6. Activated CD56
pos cells induce cell death in TCR-activated allogeneic and autologous CD4 T cells. (A) Suppression of
activated allogeneic clonal CD4 T cells by CD8 Treg (CD56
pos) cells. CD56
pos and CD56
neg cells isolated from healthy donors were stimulated with PHA
and expanded for 7–9 days. Suppression assays were performed as described in Materials and Methods. (CD56
pos, aCD3), the suppressive activity of
CD8 Treg towards CD3-activated S2B5 cells; (CD56
neg, aCD3), the suppressive activity of CD8 Tcon towards CD3-activated S2B5 cells; (CD56
pos), the
suppressive activity of CD8 Treg towards non-activated S2B5 cells; (CD56
neg), the suppressive activity of CD8 Tcon towards non-activated S2B5 cells.
*p,0.05. Results are pooled from three healthy donors (n=3). p values were calculated with unpaired two-tailed Student’s t-test compared to
(CD56
neg, aCD3). Mean and standard deviation are shown. (B) Activated CD8 Treg induce lysis of TCR-activated autologous polyclonal CD4 T cells.
Isolated CD8 Treg (CD56
pos) and CD8 Tcon (CD56
neg) were stimulated with PHA and expanded for 8–15 days. Isolated autologous polyclonal CD4 T
cells were stimulated with PHA and expanded for 8 days. Suppression assays were performed as described in Materials and Methods. (CD56
pos,
aCD3), the suppressive activity of CD8 Treg towards pre-activated autologous CD4 T cells; (CD56
neg, aCD3), the suppressive activity of CD8 Tcon
towards pre-activated autologous CD4 T cells; (CD56
pos), the suppressive activity of CD8 Treg towards non-activated autologous CD4 T cells;
(CD56
neg), the suppressive activity of CD8 Tcon towards non-activated autologous CD4 T cells. *p,0.05. Results are pooled from two independent
sorting experiments. P values were calculated with unpaired two-tailed Student’s t-test compared to (CD56
neg, aCD3). Mean and standard deviation
are shown. (C) Activated CD8 Treg induce lysis of TCR-activated allogeneic polyclonal CD4 T cells. Isolated CD56
pos and CD56
neg cells were stimulated
with PHA and expanded for 8–15 days. Isolated allogeneic polyclonal CD4 T cells were stimulated with PHA and expanded for 8–10 days. Suppression
assays were performed as described in Materials and Methods. (CD56
pos, aCD3), the suppressive activity of CD8 Treg towards pre-activated allogeneic
polyclonal CD4 T cells; (CD56
neg, aCD3), the suppressive activity of CD8 Tcon towards pre-activated allogeneic polyclonal CD4 T cells; (CD56
pos, IgE),
the suppressive activity of CD8 Treg towards isotype control mouse IgE-treated allogeneic polyclonal CD4 T cells; (CD56
neg, IgE) the suppressive
activity of CD8 Tcon towards isotype control mouse IgE-treated allogeneic polyclonal CD4 T cells. *p,0.05. Results are pooled from six healthy donors
(n=6). p-values were calculated with unpaired two-tailed Student’s t-test compared to (CD56
neg, aCD3). Mean and standard deviation are shown.
doi:10.1371/journal.pone.0059545.g006
CD161
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may be functionally related. CD27 is a member of the TNF-
receptor superfamily that is expressed on early thymocytes and
naı ¨ve T cells. All CD4
+CD45RA
+CD45RO
2 T cells [30] and
most NK cells express CD27 [39]. CD70, a unique ligand for
CD27 is transiently expressed on activated T cells, B cells and
dendritic cells. The CD27 receptor activates the NF-kB and JNK
pathways [40] and plays a critical role in B cell activation and
differentiation. On conventional T cells, CD27 expression is
increased after activation, but is subsequently downregulated as T
cells undergo proliferation and acquire effector cell function. An
inverse correlation between expression of CD27 and cytotoxic
effector function has been reported in both CD8 T cells and NK
cells [41,42]. Our analysis of conventional naı ¨ve CD8 T cells
confirmed that these cells express CD27 and this was maintained
during short term activation in vitro. In contrast, very few freshly
isolated CD8 Treg expressed CD27 even though more than 90%
of these cells are CD45RA
+CD45RO
2. Moreover, CD27
expression on CD8 Treg after PHA activation remained
significantly lower than on conventional CD8 T cells. These
observations suggest that CD8 Treg may be intrinsically primed
toward cytolytic function.
Having identified a phenotypically and functionally distinct
population of human CD8 Treg in normal peripheral blood,
further studies are needed to define the role of these cells in the
regulation of T cell responses and the molecular mechanisms that
mediate their function. The ability of CD8 Treg to selectively lyse
activated CD4 T cells appears to be a distinct functional program
that is not shared by other cytolytic cells including NK cells and
conventional cytolytic CD8 T cells. Although these cells express
CD8 and TCR, the specificity of these cells is not restricted by
expression of identical MHC class I molecules on the target cell
surface. Thus the mechanisms used by these cells to selectively
recognize and interact with activated CD4
+ T cells have not been
defined. Identification of these interacting structures will be
needed to establish the mechanisms by which these cells can
regulate immune responses in vivo. Similarly, the derivation of
these cells and their relationship to conventional CD8 T cells is
also an important area for further investigation. However, the
identification of a distinct population of CD8 T cells with the
ability to selectively regulate activated CD4 T cells is a critical step
in the functional characterization of these cells and will also allow
the characterization of these cells in different clinical conditions.
Materials and Methods
Antibodies
Monoclonal antibodies (mAb) for CD3, CD8a, CD8b, CD25,
CD56, CD62L, CD69, CD94, CD161, Va24, Vb11 and NKG2a
cell surface staining were obtained from Beckman Coulter (Brea,
CA). Additional mAbs for CD3, CD8a, CD27, CD28, CD45RA,
CD45RO, CD56, CD62L, CD94, CD127 and CD161 were
purchased from Biolegend (San Diego, CA). Mouse anti-human
CD3 IgE mAb (RDI-M1654clb) was purchased from Research
Diagnostics Inc (Flanders, NJ). Purified mouse IgE mAb was
purchased from Biolegend (San Diego, CA).
Cells and Culture
Normal PBMC were isolated from donor leukopack samples
provided by the Dana-Farber Cancer Institute Blood Donor
Center after Ficoll-Paque (Amersham Pharmacia Biotech) separa-
tion. Normal PBMC were also isolated from blood samples from
healthy subjects after written consent, which was approved by the
institutional review board of the Brigham and Women’s hospital.
EBV-transformed B cell lines (LCL) were maintained in RPMI
1640 (Mediatech, Inc) supplemented with 10% heat-inactivated
FBS, 2 mM glutamine, 1 mM sodium pyruvate, 10 mM Hepes,
50 I U/ml penicillin and 50 mg/ml streptomycin. T cell clones or
lines were maintained and expanded via stimulation with PHA.
Briefly, T cells were first stimulated with 1.2 mg/ml PHA (PHA-L,
Sigma) in Iscove’s Modified Dulbecco’s Medium (IMDM-Invitro-
gen) supplemented with 10% heat-inactivated human AB serum
(FBS for S2B5 cells), 100 u/ml recombinant human IL-2 (rIL-2),
50 I.U/ml penicillin and 50 mg/ml streptomycin (complete
IMDM) in the presence of irradiated PBMC (3,500 cGy, 1610
6
or 3610
6 cells/well) and LCL (6,000 cGy, 2610
5 or 6610
5 cells/
well) as feeder cells in 24-well plates. Culture medium (complete
IMDM with rIL-2) was changed every 2 to 3 days.
Flow Cytometric Analysis of Cell Surface Antigen
Expression
To characterize human peripheral blood, PBMC were labeled
with FITC-conjugated aCD3, PC7-conjugated aCD8, PE-conju-
gated aCD161 and PC5-conjugated aCD56 followed by FACS
analysis with a BD FACSCanto II (Figure 1). To analyze the cell
surface antigen expression profile of CD3
+CD8
+CD161
2CD56
+
cells, PBMC were labeled with Brilliant Violet 605
TM-conjugated
aCD3, Pacific Blue
TM-conjugated aCD8, PC5-conjugated
aCD56, Alexa FluorH 647-conjugated aCD161, PC7-conjugated
aCD45RA, FITC-conjugated aCD27, aCD127 or aCD94 and
PE-conjugated aCD25, aCD45RO, aCD62L, aCD69 or aN-
KG2a followed by FACS analysis with a BD LSR II flow
cytometer (Figure 2 and 3). To analyze the cell surface antigen
expression profile of isolated CD8 T cell subsets after PHA
stimulation, cells were labeled with FITC-conjugated aCD3, PC7-
conjugated aCD8, PC5-conjugated aCD56 and PE-conjugated
aCD27, aCD45RA, aCD45RO, aCD62L, aCD94, aCD161,
aNKG2a or aVa24 followed by FACS analysis with a BD
FACSCanto II (Figure 5).
Isolation of CD8 Treg from PBMC
PBMC were labeled with FITC-conjugated aCD3, PC7-
conjugated aCD8, PE-conjugated aCD161 and PC5-conjugated
aCD56. CD3
+CD8
+CD161
2CD56
+ (CD56
pos) and
CD3
+CD8
+CD161
2CD56
2 (CD56
neg) cells were isolated with a
fluorescence activated cell sorter (BD FACSAria
TM). An aliquot of
isolated CD56
pos cells was stained with PE-conjugated aCD8b or
aVa24 followed by FACS analysis with a BD FACSCanto II
(Figure 4B). Isolated CD56
pos and CD56
neg cells were stimulated
with 1.2 mg/ml PHA in complete IMDM with human AB serum
in the presence of feeder cells and rIL-2 (100 u/ml) in 24-well
plates as described above. Culture medium (complete IMDM with
rIL-2) was changed every 2 to 3 days, or when media turned
yellow. Cells were cultured for 7–15 days before being analyzed
for suppressive activity.
Wright-Giemsa Stain
Cells isolated from PBMC were suspended in complete IMDM
at a concentration of 1610
5 cells/ml or lower. Cells (100 ml per
slide) were mounted onto slides through cytospin. After drying
overnight, cells were stained with Wright-Giemsa reagents.
Staining was visualized using a bright-field microscope (Leica
DC300).
CD8 Treg Suppressive Activity Assay (CytoTx Flow assay)
Assays were performed and interpreted as described previously
[22]. Briefly, CD4 T cells (target) and CD8 T cells (effector) were
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target and effector cells were labeled with 3,39 dihexyloxacarbo-
cyanine (DiOC6) (Molecular Probe) (1.5 nM) for 10 min at 37uC.
After being washed with IMDM, target cells were labeled with PC-
7-conjugated anti-CD4 antibodies for 20 min on ice. Both target
and effector cells were resuspended in IMDM supplemented with
10% FBS and antibiotics. Target cells (1–3610
6/ml) were then
incubated for 3 hr at 37uC in the presence or absence (as control)
of aCD3 IgE (1 mg/ml) in a tissue culture incubator. In some
experiments, purified mouse IgE antibody (1 mg/ml) was used as
isotype control for aCD3 IgE to treat target cells. After extensive
washing, target cells (1–3610
5) were mixed with effector cells in a
U-bottomed 96-well plate at various E/T ratios. After 4 hr of
incubation at 37uC under 5% CO2, cells were harvested and
analyzed by flow cytometry. Percent cytotoxicity was calculated as
follows: 1006(% of total apoptotic target cells – % of spontaneous
apoptotic target cells)/(100 2 % of spontaneous apoptotic target
cells).
Statistical Analysis
Data are expressed as mean6SD. Differences between groups
were tested via unpaired two-tailed Student’s t-test.
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